Catalent to buy CDMO Paragon Bioservices for $1.2bn

This article was originally published here

Paragon Bioservices is a major viral vector development and manufacturing partner for gene therapies. Paragon president and CEO Pete Buzy said: “We are excited to join forces with

The post Catalent to buy CDMO Paragon Bioservices for $1.2bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply